Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMEL1 | Q495T6 | 1/20 | 0.52 |
| ▸ | ACE | P12821 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.47 |
| ▸ | PREP | P48147 | 3/20 | 0.46 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.46 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19880369 | 0.96 | SMN1; SMN2 (0.51) | MMEL1ACESMN1; SMN2NPC1RAB9A | |
| SCHEMBL18734805 | 0.96 | SMN1; SMN2 (0.51) | MMEL1ACESMN1; SMN2NPC1RAB9A | |
| SCHEMBL19880370 | 0.96 | SMN1; SMN2 (0.51) | MMEL1ACESMN1; SMN2NPC1RAB9A | |
| SCHEMBL24705627 | 0.90 | SPHK1 (0.50) | MMEL1SMN1; SMN2NPC1RAB9ACTRB1 | |
| SCHEMBL20966402 | 0.90 | SPHK1 (0.58) | MMEL1SMN1; SMN2CTRB1PREPSPHK1 | |
| SCHEMBL18626013 | 0.90 | SPHK1 (0.50) | MMEL1SMN1; SMN2NPC1RAB9ACTRB1 | |
| SCHEMBL934366 | 0.87 | MMEL1 (0.58) | MMEL1ACECTRB1PREPFKBP1A | |
| SCHEMBL20966406 | 0.87 | MMEL1 (0.53) | MMEL1ACESMN1; SMN2CTRB1PREP | |
| SCHEMBL2707345 | 0.87 | MMEL1 (0.58) | MMEL1ACECTRB1PREPFKBP1A | |
| SCHEMBL20993944 | 0.86 | MMEL1 (0.65) | MMEL1SMN1; SMN2NPC1FKBP1AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2578587-B1 | PYRAZOLE DERIVATIVES | HANDE STARLAKE BIOSCIENCE CO LTD (CN) | 2016-09-07 | — | — | EP | disclosed |
| US-9249172-B2 | Pyrazole derivatives | HANDE PHARMA LIMITED (CN) | 2016-02-02 | — | — | US | disclosed |
| US-20130142757-A1 | PYRAZOLE DERIVATIVES | HANDE STARLAKE BIOSCIENCE CO., LTD. (CN) | 2013-06-06 | — | — | US | disclosed |
| EP-2578587-A1 | PYRAZOLE DERIVATIVES | Hande Starlake Bioscience Co., Ltd. (CN) | 2013-04-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130142757-A1 | PYRAZOLE DERIVATIVES | CBR3, CBR1, CYP2E1 | MMEL1 4341/4885ACE 1889/4885SMN1; SMN2 4440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.